Last updated: February 19, 2026
This report analyzes key considerations for securing and enforcing biopharmaceutical patents in Vietnam, focusing on patentability requirements, enforcement mechanisms, and typical claim scope for novel biological entities and associated technologies.
What are the Core Patentability Requirements for Biopharmaceuticals in Vietnam?
Vietnam's Law on Intellectual Property (LIP) establishes patentability criteria applicable to all inventions, including biopharmaceuticals. Novelty, inventive step, and industrial applicability are fundamental [1].
Novelty
An invention is novel if it has not been disclosed to the public anywhere in the world before the filing date or priority date of the patent application [1]. For biopharmaceuticals, this means the specific nucleotide or amino acid sequence, or a novel function or therapeutic use of a known substance, must not have been publicly disclosed through publications, presentations, or commercialization prior to filing. Prior art searches are critical to establish novelty.
Inventive Step
An invention possesses an inventive step if, compared to the prior art, it is not obvious to a person skilled in the art [1]. For biopharmaceuticals, demonstrating an inventive step often involves showing unexpected technical effects or advantages. This can include:
- Improved efficacy: A new drug molecule exhibiting superior therapeutic outcomes compared to existing treatments.
- Reduced side effects: A biologic with a more favorable safety profile.
- Novel mechanism of action: A compound acting via a previously unknown pathway.
- New therapeutic indications: Discovering a new use for an existing drug.
- Manufacturing improvements: A novel, more efficient, or cost-effective method of producing a known biologic.
Comparative data, such as in vitro and in vivo studies, clinical trial results, and pharmacological data, are essential to support claims of an inventive step.
Industrial Applicability
An invention is industrially applicable if it can be made or used in any kind of industry, including agriculture, manufacturing, and services [1]. For biopharmaceuticals, this requirement is generally met if the invention is capable of being produced on a commercial scale and has a practical application in medicine or diagnostics.
Exclusions from Patentability
The LIP specifically excludes certain subject matter from patentability [1]. For biopharmaceuticals, key exclusions include:
- Discoveries, scientific theories, and mathematical methods.
- Schemes, plans, rules, and methods for performing mental acts, training animals, playing games, doing business, and performing services.
- Computer programs.
- Methods of treatment of human or animal bodies by surgery or therapy and diagnostic methods practiced on the human or animal body. This exclusion is particularly relevant. While the product (e.g., a drug molecule) is patentable, the method of using that product to treat a disease is generally not. However, claims directed to the use of a patented substance for treating a specific disease (e.g., "Use of Compound X for treating Alzheimer's disease") are often permissible as second medical use claims in many jurisdictions, and this approach is generally accepted in Vietnam. Claims for medical devices or diagnostic kits are patentable if they meet other criteria.
- Plants and animals, and essentially biological processes for the production of plants or animals. However, microbiological processes and the products thereof are patentable. This distinction is critical for genetically modified organisms (GMOs) and cell lines used in biopharmaceutical production.
What is the Typical Claim Scope for Biopharmaceutical Patents in Vietnam?
The scope of patent claims dictates the extent of protection afforded to an invention. For biopharmaceuticals, claim drafting must be precise to encompass novel entities, their uses, and manufacturing processes.
Compound Claims
Claims directed to novel active pharmaceutical ingredients (APIs), whether small molecules or large biomolecules (e.g., antibodies, proteins, peptides), are central. These claims typically define the compound by its chemical structure (e.g., Markush structures for small molecules) or its sequence (e.g., nucleotide or amino acid sequences for biologics). Claims can also be directed to salts, polymorphs, isomers, or specific formulations of the API.
Formulation Claims
These claims cover specific pharmaceutical compositions containing the API and excipients. They are crucial for providing protection beyond the active ingredient itself, particularly when the API is known or its patent is close to expiry. Effective formulation claims can define the proportions of ingredients, specific excipients, dosage forms (e.g., tablets, capsules, injectables), and release profiles (e.g., sustained release).
Method of Use Claims
As noted, direct methods of treatment are unpatentable. However, Vietnam permits "use claims" that describe the application of a patented product for a specific medical purpose. These are typically structured as:
- First Medical Use: "Compound X for use as a therapeutic agent." This is broad and protects the compound itself for any therapeutic purpose.
- Second Medical Use: "Compound X for use in treating [specific disease Y]." This is crucial for protecting new indications discovered for existing drugs. These claims are vital for lifecycle management and extending market exclusivity.
Process Claims
Claims directed to the methods of manufacturing the biopharmaceutical are also important. These can cover:
- Synthesis methods: For small molecules, defining novel chemical synthesis routes.
- Bioprocessing methods: For biologics, defining specific fermentation conditions, purification techniques, cell culture media, or genetic engineering steps used to produce the molecule. Claims can also cover the intermediate products or specific reagents used in these processes.
Polymorph and Salt Claims
If a novel polymorph or salt form of a known API exhibits advantageous properties (e.g., improved solubility, stability, bioavailability), it can be independently patentable. Claims would specifically define the crystalline form or salt structure.
Claims to Biological Materials
Claims can also cover specific biological materials used in research or therapy, such as:
- Cell lines: For the production of biologics or for research.
- Vectors: For gene therapy or protein expression.
- Antibodies: Including specific hybridoma cell lines that produce monoclonal antibodies.
The precise scope of these claims depends on the level of specificity and novelty demonstrated.
How are Biopharmaceutical Patents Enforced in Vietnam?
Enforcement of patent rights in Vietnam involves civil remedies, primarily through the People's Courts or the Vietnam Intellectual Property Research Institute (VIPRI) for arbitration.
Infringement Actions
Patent infringement occurs when a third party makes, uses, sells, offers for sale, or imports a patented invention without the patent holder's consent [1]. For biopharmaceuticals, infringement can involve:
- Unauthorized manufacture: Producing a patented API or drug product.
- Unauthorized sale or offer for sale: Marketing or selling a patented drug.
- Unauthorized importation: Bringing a patented drug into Vietnam without authorization.
- Use of a patented process: Employing a patented method for manufacturing a drug.
Legal Avenues for Enforcement
- Civil Lawsuit: The patent holder can file a lawsuit with the competent People's Court. The court can issue preliminary injunctions to prevent further infringement and award damages, including lost profits and reasonable royalties. Corrective measures, such as destroying infringing goods, may also be ordered.
- Arbitration: Parties can agree to resolve disputes through arbitration at VIPRI or other arbitration centers. Arbitration decisions are binding.
- Administrative Actions: While less common for direct patent infringement, administrative bodies like the Market Management Department (under the Ministry of Industry and Trade) can take action against counterfeit goods, which may indirectly involve patented products. However, their focus is typically on trademarks and unfair competition rather than direct patent infringement.
Evidentiary Challenges
Enforcing biopharmaceutical patents can present significant evidentiary challenges, particularly in proving infringement of process claims or the composition of imported generic products.
- Product-by-Process Claims: If a patent claims a product made by a specific process, proving infringement may require demonstrating that the infringing product was made using the patented process, which can be difficult without access to the manufacturing details of the infringing party.
- Composition of Matter: For imported products, determining their exact composition and whether they infringe a composition of matter claim can require expert analysis and potentially discovery processes, which can be complex in Vietnam.
- Data Exclusivity: Vietnam has a system of data exclusivity that protects clinical trial data submitted to regulatory authorities for drug registration. This is distinct from patent protection but can prevent generic manufacturers from relying on the innovator's data for a certain period, indirectly supporting market exclusivity for patented drugs. This protection typically lasts for five years from the date of first marketing authorization [2].
Damages and Remedies
When infringement is proven, remedies can include:
- Injunctions: Cessation of infringing activities.
- Damages: Compensation for losses incurred by the patent holder. This can be based on lost profits, a reasonable royalty, or the profits made by the infringer.
- Destruction of infringing goods: Physical elimination of the infringing products.
The calculation of damages is a critical aspect of enforcement, and the patent holder must provide sufficient evidence to support their claim.
What are the Trends and Considerations for Biopharmaceutical Patents in Vietnam?
The Vietnamese market is growing, with increasing interest from both domestic and international pharmaceutical companies. Key trends and considerations include:
Increasing R&D Investment
Vietnam's government is encouraging investment in high-technology sectors, including biotechnology and pharmaceuticals. This is leading to greater domestic innovation and a corresponding need for robust intellectual property protection [3].
Focus on Generics vs. Innovators
While Vietnam is a significant market for generic drugs, there is a growing emphasis on fostering innovation and attracting investment in novel drug development. This dual focus influences patent policy and enforcement priorities.
Alignment with International Standards
Vietnam is a signatory to various international treaties, including the TRIPS Agreement, which requires member states to provide adequate and effective patent protection for pharmaceutical inventions. While there can be nuances in application, the general direction is towards alignment with global IP standards [4].
Challenges in Patent Prosecution
- Office Actions: Examiners may raise objections related to novelty, inventive step, or clarity. Careful responses, supported by robust evidence, are crucial.
- Claim Interpretation: The interpretation of claim scope by examiners and courts can influence the breadth of protection. Drafting claims with clear definitions and supporting data is paramount.
- Enforcement Uncertainty: While the legal framework exists, the practical application of enforcement mechanisms can sometimes be a concern for patentees, requiring careful legal strategy.
Strategic Patent Filing
- Early Filing: Filing patent applications as early as possible, ideally before any public disclosure, is critical.
- Global Strategy: Pharmaceutical companies typically pursue patent protection in key markets globally. Vietnam is increasingly considered as part of this strategy.
- Patent Term Extension: While Vietnam's LIP does not explicitly provide for patent term extensions (PTE) as found in some other jurisdictions to compensate for regulatory approval delays, the effective period of protection can be influenced by the interplay of patent filing, grant dates, and data exclusivity periods. Companies should monitor evolving IP regulations.
Key Takeaways
- Biopharmaceutical patentability in Vietnam hinges on novelty, inventive step, and industrial applicability, with specific exclusions for methods of human/animal treatment.
- Claim scope for biopharmaceuticals typically covers novel compounds, formulations, approved methods of use for specific diseases, and manufacturing processes.
- Patent enforcement is primarily through civil litigation, with remedies including injunctions and damages, though evidentiary challenges can exist.
- Data exclusivity for five years following marketing authorization offers an additional layer of protection for innovative medicines.
- Vietnam's IP landscape is evolving, with increasing alignment with international standards and a growing emphasis on both innovation and generic competition.
Frequently Asked Questions
-
Can methods of gene therapy be patented in Vietnam?
Methods of gene therapy involving surgical or therapeutic interventions on the human body are generally excluded from patentability. However, the specific gene constructs, vectors, or compositions used in gene therapy, if novel and inventive, are likely patentable.
-
What is the typical duration of patent protection for biopharmaceuticals in Vietnam?
The standard patent term in Vietnam is 20 years from the filing date. There is no explicit provision for patent term extension based on regulatory approval delays as seen in some other countries.
-
How can I prove infringement of a process patent for a biopharmaceutical if I don't have access to the infringer's manufacturing data?
Proving infringement of process patents without direct access can be challenging. Strategies include:
- Analyzing the resulting product for characteristics indicative of the patented process.
- Seeking discovery orders from the court if possible.
- Leveraging information from public disclosures or regulatory filings if available.
- Relying on presumption of infringement if a patent is granted for a product and the defendant is producing the identical product without license.
-
Are antibodies patentable as a class, or must each specific antibody be claimed individually?
Each specific antibody that meets the patentability requirements (novelty, inventive step, industrial applicability) can be patented. Claims typically define antibodies by their sequence, epitope binding, or functional characteristics. Broad claims to entire classes of antibodies may face challenges if they are not sufficiently supported by data or if the scope is overly broad compared to the disclosed invention.
-
Does Vietnam recognize the concept of "evergreening" through patenting minor modifications of existing drugs?
Vietnam's patent law, like most jurisdictions, requires a genuine inventive step for patentability. Minor modifications that do not result in unexpected technical advantages or improvements are unlikely to be considered inventive and may be refused by the patent office. However, if a minor modification leads to a significant and unexpected improvement (e.g., dramatically reduced toxicity, improved bioavailability), it could potentially be patentable.
Cited Sources
[1] The Law on Intellectual Property of Vietnam, as amended. (Current version available through official Vietnamese government sources and IP law firms specializing in Vietnam).
[2] Decree No. 76/2017/ND-CP detailing a number of articles of the Law on Intellectual Property regarding copyright and related rights, industrial property rights, and the protection of industrial property rights and the procedures for patent registration. (Specific provisions concerning data exclusivity are detailed within related decrees and circulars).
[3] Vietnam Ministry of Planning and Investment. (Ongoing reports and policy documents on foreign direct investment and high-technology development).
[4] World Trade Organization. (Agreement on Trade-Related Aspects of Intellectual Property Rights - TRIPS Agreement).
